Dextromethorphan-Bupropion Delays Relapse of Alzheimer Disease Agitation
AXS-05 is an investigational agent consisting of a proprietary formulation of dextromethorphan and bupropion.
Diagnosis & Disease Information
Gantenerumab Fails to Meet Endpoints in Early Alzheimer Disease Trials
Gantenerumab is an investigational immunoglobulin G1 antibody designed to increase the clearance of soluble amyloid beta from the brain.
July 2022 Recap: Drug Pipeline Updates
Stay up-to-date on the latest drugs in development.
June 2022 Recap: Drug Pipeline Updates
Stay up-to-date on the latest drugs in development.
Lecanemab Gets Priority Review for Early Alzheimer Disease
Lecanemab is an investigational anti-amyloid beta protofibril antibody.
COVID-19 Linked to Increased Risk of Neurological Disorders
Most neurological disorders do not appear to be more frequent after COVID-19 than after influenza or bacterial pneumonia
Crenezumab Misses Endpoints in Autosomal Dominant Alzheimer Disease Trial
Crenezumab is an investigational monoclonal antibody designed to neutralize neurotoxic oligomers, a form of beta-amyloid.
Reductions in Amyloid Beta Plaques, P-Tau Seen With Aducanumab Over 2 Years Later
The long-term extension phase of the phase 3 EMERGE and ENGAGE trials evaluated the efficacy and safety of aducanumab-avwa in adults aged 50 to 85 years with early Alzheimer disease.
Donepezil Transdermal Patch Approved for Alzheimer Disease
Adlarity is a once-weekly transdermal formulation of donepezil that is designed to be worn for 7 days with consistent adhesion.
